CN Patent

CN116916907A — 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物

Assigned to United States Government Represented By Secretary Of Health And Human Services · Expires 2023-10-20 · 3y expired

What this patent protects

本公开提供了一种用治疗有效量的式(I)化合物(特别是CLTX‑305)治疗常染色体显性遗传性1型低钙血症(ADH1)的方法，其中所述化合物的治疗有效量将血钙浓度(cCa)增加至约7.5mg/dL至约10.5mg/dL的范围，例如约8.5mg/dL至约10.5mg/dL。本文还提供了根据一种或多种给药方案用治疗有效量的式(I)或CLTX‑305的化合物治疗常染色体显性遗传性低钙血症1型(ADH1)的给药方法。

USPTO Abstract

本公开提供了一种用治疗有效量的式(I)化合物(特别是CLTX‑305)治疗常染色体显性遗传性1型低钙血症(ADH1)的方法，其中所述化合物的治疗有效量将血钙浓度(cCa)增加至约7.5mg/dL至约10.5mg/dL的范围，例如约8.5mg/dL至约10.5mg/dL。本文还提供了根据一种或多种给药方案用治疗有效量的式(I)或CLTX‑305的化合物治疗常染色体显性遗传性低钙血症1型(ADH1)的给药方法。

Drugs covered by this patent

paltusotine-hydrochloride (PALTUSOTINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN116916907A
Jurisdiction: CN
Classification: —
Expires: 2023-10-20
Drug substance claim: No
Drug product claim: No
Assignee: United States Government Represented By Secretary Of Health And Human Services
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.